Zeneca's goserelin acetate for breast cancer
Executive Summary
NDA supplement filed for implant formulation of goserelin acetate (Zoladex in oral form) in treating advanced breast cancer in premenopausal and perimenopausal women. The supplemental application is based on results of trials involving more than 800 women in North America and Europe. Zeneca says Zoladex "provides response rates and survival benefits comparable to those achieved by other standard treatments such as surgical oophorectomy or irradiation of the ovaries"...